ArticleTranslational neurodegeneration2023

An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers.

Katherine E Olson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.